Rheumatoid Arthritis Market
Rheumatoid Arthritis Market Study by Serology and Monitoring Rheumatoid Arthritis Treatment Efficiency Tests for Hospitals, Diagnostic Laboratories, and Ambulatory Surgical Centers from 2024 to 2034
Analysis of Rheumatoid Arthritis Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Rheumatoid Arthritis Market Outlook (2024 to 2034)
The global rheumatoid arthritis market size is estimated at a valuation of US$ 857.5 million in 2024 and is projected to reach US$ 1.56 billion by the end of 2034, expanding at a CAGR of 6.2% over the next ten years.
Demand for rheumatoid arthritis medicines has spiraled upward in recent years as people’s understanding of their health is rising. Rheumatoid arthritis is a chronic inflammatory disorder that predominantly affects the joints. This condition can damage various body systems such as the skin, eyes, lungs, heart, and blood vessels, as the immune system attacks healthy tissues, weakening the individual and increasing the risk of mortality.
In recent years, a growing focus on health and fitness has led people to recognize the importance of health. This trend has directly influenced arthritis drug manufacturers, contributing to rheumatoid arthritis market growth.
- According to the Centers for Disease Control and Prevention, the onset of rheumatoid arthritis is two to three times more likely in females than in males. This analysis has provided valuable insights to suppliers, prompting them to prioritize female patients and improve drug components to enhance their presence in the market.
Adults aged 60 to 65 are susceptible to this disease. By prioritizing adult females, suppliers are capitalizing on this demographic, thus contributing to the overall expansion of the rheumatoid arthritis market. The most common medications for RA fall into five categories: non-steroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying anti-rheumatic drugs (DMARDs), biologics, and Janus kinase inhibitors. Suppliers ensure a consistent supply of these medications to maintain market dominance and outperform competitors.
Another strategy employed by suppliers is collaboration with hospitals, clinics, and healthcare providers to identify areas for improvement in the supply chain. This collaborative approach results in effective and efficient growth in supply throughout the year.
- The Japanese market is projected to expand at a CAGR of 6.9% from 2024 to 2034.
| Report Attributes | Details |
|---|---|
| Rheumatoid arthritis Market Size (2024E) | US$ 857.5 Million |
| Forecasted Market Value (2034F) | US$ 1.56 Billion |
| Global Market Growth Rate (2024 to 2034) | 6.2% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 5.2% CAGR |
| China Market Value (2034F) | US$ 173 Million |
| North America Market Share (2024E) | 39.7% |
| East Asia Market Share (2034F) | 15% |
| Key Companies Profiled | AbbVie Inc; Johnson & Johnson Innovative Medicine; Amgen Inc.; Pfizer Inc.; Novartis AG; Sanofi SA; Bristol Myers Squibb; Celgene Corporation |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Healthcare Trends are Driving Adoption of Tests for Rheumatoid Arthritis?
“Rising Prevalence of Autoimmune Diseases”
Increasing incidence of autoimmune disorders, such as rheumatoid arthritis, has prompted the need for quick diagnostic test solutions that would cut down on the time and effort needed for sample testing. Consequently, the commercialization of innovative quick diagnostic test kits possessing elevated specificity and sensitivity is the primary focus of makers of autoimmune disease test kits.
Due to the low specificity of current diagnostic techniques, doctors are increasingly adopting the practice of using several tests (such as rheumatoid factor and antinuclear antibody tests) to diagnose rheumatoid arthritis. The effectiveness of rheumatoid arthritis therapy is tracked using a combination of testing techniques. Therefore, the demand for rheumatoid arthritis diagnostic test kits is projected to rise.
“Growing Government Assistance to Provide Innovative and Affordable Medications”
One of the main factors projected to fuel the expansion of the rheumatoid arthritis market size during the forecast period is the increased investments by governments in the development of innovative and affordable medications for rheumatoid arthritis surveillance and treatment. To lessen their burden in monitoring and treating rheumatoid arthritis, government agencies are funding research and development projects.
Controlling the global spread of rheumatoid arthritis is largely dependent on government assistance for diagnosis and surveillance of the disease. Over the projection period, increasing spending on monitoring epidemiology and surveillance of rheumatoid arthritis is projected to contribute to an increase in the number of cases.
Rheumatoid arthritis does not currently have a viable therapy. However, as an off-label therapy, doctors typically give anti-inflammatory medications to people with rheumatoid arthritis, which helps lessen joint inflammation. Global demand for rheumatoid arthritis diagnosis test kits and treatment efficacy monitoring test kits has surged as a result of doctors prescribing more medications off-label. Due to their high sensitivity and specificity, the antinuclear antibody (ANA) and anti-cyclic citrullinated peptide (anti-CCP) test segments are predicted to lead the market.
What is Affecting the Profit Margins of Rheumatoid Arthritis Testing Providers?
“Limited Reliability and Accuracy of RA Test Kits”
One major obstacle limiting the development of rheumatoid arthritis test kits at the moment is their inadequate sensitivity and specificity in comparison to other test kits on the market. The specificity and sensitivity of conventional test techniques, such as erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF) testing, are restricted. Test findings from cutting-edge diagnostic test kits, such as antinuclear antibody (ANA) and anti-cyclic citrullinated peptide (anti-CCP) assays, have excellent sensitivity and specificity. Because of their high cost, increasing the uptake of diagnostic tests is a considerable problem.
Specificity and sensitivity of conventional testing for the diagnosis of rheumatoid arthritis are restricted. As a result, test results have a maximum false positive rate. An elevated occurrence of false positive outcomes could undermine the reliability of rheumatoid arthritis diagnosis test kits, potentially impeding market expansion. Widespread utilization of traditional rheumatoid arthritis testing methods, such as the RF test and ESR test, has led to an increase in the positivity ratio in rheumatoid arthritis testing, encompassing both true and false positives.
Due to the difficulty in determining the underlying etiology of rheumatoid arthritis, test kits for the condition are now confronting issues with specificity and sensitivity. Combination testing has been used by doctors to identify and track the development of rheumatoid arthritis. As a result, the price of combination test kits for diagnosis is rising.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Evaluation
The South Korean market is projected to expand at a CAGR of 6% from 2024 to 2034.
Why is the United States a Commercially Viable for Rheumatoid Arthritis Test Kit Suppliers?
“Government Initiatives and Educational Campaigns to Raise Awareness of Rheumatoid Arthritis”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 275 Million |
| Growth Rate (2024 to 2034) | 5.6% CAGR |
| Projected Value (2034F) | US$ 474 Million |
The United States government is taking proactive steps to address the increasing incidence of rheumatoid arthritis to educate citizens about the disease and facilitate its treatment. For suppliers, this presents a prime opportunity to establish dominance in the United States market and significantly expand their presence.
- According to 2021 data from the Centers for Disease Control and Prevention (CDC), arthritis affects 24% of adult Americans, totaling 58.5 million individuals. This condition severely impacts individuals' ability to work and incurs an annual cost of US$ 303.5 billion to the country, covering missed income and medical expenses. Rheumatoid arthritis, lupus, gout, and osteoarthritis are among the most prevalent forms of arthritis, with 57.3% of working-age individuals (aged 18 to 64) in the country affected.
What Makes China an Investment-worthy Market for Rheumatoid Arthritis Testing Providers?
“Increasing Prevalence of Rheumatoid Arthritis among Elderly Population”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 94 Million |
| Growth Rate (2024 to 2034) | 6.4% CAGR |
| Projected Value (2034F) | US$ 173 Million |
The market in China is being mainly driven by an increase in the elderly population that is more susceptible to ailments such as rheumatoid arthritis.
- The Asian Development Bank states that by 2050, one in four individuals in Asia Pacific is projected to be over 60. Between 2010 and 2050, the number of senior people (those over 60) in the region is expected to increase three times, approaching 1.3 billion. This creates a lucrative market that allows the providers to maximize their earnings and reap their profits from this commercially fertile market.
Category-wise Insights
More suppliers are reaching out to diverse end users to provide their medications, including hospitals, diagnostic laboratories, private clinics, public healthcare facilities, and ambulatory surgical centers. Among these, the private laboratories segment is projected to expand at a CAGR of 4.6% from 2024 to 2034.
Why are Serology Tests Extensively Adopted for Detection of Rheumatoid Arthritis?
“Accuracy of Serology Tests in Detecting Antibodies in Blood Samples”
| Attribute | Serology |
|---|---|
| Segment Value (2024E) | US$ 647.7 Million |
| Growth Rate (2024 to 2034) | 6.7% CAGR |
| Projected Value (2034F) | US$ 1.23 Billion |
People suffering from rheumatoid arthritis prefer serology over other available tests, as the former accurately detects antibodies or other harmful agents in blood samples. Serology is also preferred due to its cost-effectiveness, contributing to its growing popularity as a testing method. Immunoassays represent the most commonly utilized serological tests. Point-of-care (POC) tests are employed in diagnostic procedures for detecting antigens, antibodies, and nucleic acids.
Which End User Accounts for a Significant Market Share?
“Preference for Diagnostic Laboratories Driven by Reliable Results”
| Attribute | Diagnostic Laboratories |
|---|---|
| Segment Value (2024E) | US$ 270 Million |
| Growth Rate (2024 to 2034) | 8.2% CAGR |
| Projected Value (2034F) | US$ 592.4 Million |
When individuals undergo testing for rheumatoid arthritis, they typically undergo a series of tests to determine the specific symptoms present in the body. These diagnostic procedures predominantly occur in diagnostic laboratories, making them the preferred choice for reliable and trustworthy test results.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Rivalry
Key players in the rheumatoid arthritis market aim to reach a worldwide consumer base by utilizing their wide distribution network to provide their products at every stage of the supply chain. Manufacturers are acquiring businesses specializing in rheumatoid arthritis-related products to meet the growing demand for rheumatoid arthritis diagnosis solutions.
Important producers are also focusing on cutting-edge research, such as biomarker-based rheumatoid arthritis diagnostic techniques, which are projected to open up new business prospects for producers of rheumatoid arthritis test kits, contributing to the evolving rheumatoid arthritis market trends.
- A Biocon Ltd. subsidiary, Biocon Biologics Ltd., announced in July 2023 that HULIO (adalimumab-flip) injectable, a biosimilar of Humira (adalimumab), was now available in the United States for the treatment of rheumatoid arthritis.
Key Segments of Rheumatoid Arthritis Market Research
-
By Test Type :
- Serology Tests
- Erythrocyte Sedimentation Rheumatoid Arthritis (ESR)
- Rheumatoid Factor (RF)
- Anti-cyclic Citrullinated Peptide (anti-CCP)
- Antinuclear Antibody (ANA)
- Uric Acid
- Monitoring Rheumatoid Arthritis Treatment Efficiency Tests
- Salicylate Level Count
- Muscle Enzyme Tests
- Creatinine Tests
- Serology Tests
-
By End User :
- Hospitals
- Diagnostic Laboratories
- Private Laboratories
- Public Laboratories
- Ambulatory Surgical Centers
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Market Background
- 6. Global Market Volume (Units) Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 7. Global Market - Pricing Analysis
- 8. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Product Type
- 9.1. Serology Tests
- 9.2. Monitoring Treatment Efficiency Tests
- 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by End User
- 10.1. Hospitals
- 10.2. Diagnostic Laboratories
- 10.3. Ambulatory Surgical Centers
- 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Europe
- 11.4. East Asia
- 11.5. South Asia
- 11.6. Oceania
- 11.7. Middle East and Africa (MEA)
- 12. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 13. Latin America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 14. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 15. South Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 16. East Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 17. Oceania Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 18. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 19. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 20. Market Structure Analysis
- 21. Competition Analysis
- 21.1. AbbVie Inc
- 21.2. Johnson & Johnson Innovative Medicine
- 21.3. Amgen Inc.
- 21.4. Pfizer Inc.
- 21.5. Novartis AG
- 21.6. Sanofi SA
- 21.7. Bristol Myers Squibb
- 21.8. Celgene Corporation
- 22. Assumptions and Acronyms Used
- 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2018 to 2034, By Product Type
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product Type
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By End User
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product Type
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By End User
Table 08: Latin America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product Type
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By End User
Table 11: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product Type
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By End User
Table 14: South Asia Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product Type
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By End User
Table 17: East Asia Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product Type
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By End User
Table 20: Oceania Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product Type
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By End User
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Product Type
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2018 to 2023
Figure 02: Global Market Volume Forecast (in 000' Units), 2024 to 2034
Figure 03: Pricing Analysis (US$) Per Product Type, By Region, 2023
Figure 04: Pricing Analysis (US$) Per Product Type, By Region, 2023
Figure 05: Global Market Value Analysis (US$ Mn), 2018 to 2023
Figure 06: Global Market Value Forecast (US$ Mn), 2024 to 2034
Figure 07: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 08: Global Market Share Analysis (%), By Product Type, 2024 to 2034
Figure 09: Global Market Y-o-Y Analysis (%), By Product Type, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 11: Global Market Share Analysis (%), By End User, 2024 to 2034
Figure 12: Global Market Y-o-Y Analysis (%), By End User, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by End User, 2024 to 2034
Figure 14: Global Market Share Analysis (%), By Region, 2024 to 2034
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value Share, By Product Type, 2024 (E)
Figure 18: North America Market Value Share, By End User, 2024 (E)
Figure 19: North America Market Value Share, By Country, 2024 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2018 to 2023
Figure 21: North America Market Value Forecast (US$ Mn), 2024 to 2034
Figure 22: North America Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 24: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 25: Latin America Market Value Share, By Product Type, 2024 (E)
Figure 26: Latin America Market Value Share, By End User, 2024 (E)
Figure 27: Latin America Market Value Share, By Country, 2024 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2018 to 2023
Figure 29: Latin America Market Value Forecast (US$ Mn), 2024 to 2034
Figure 30: Latin America Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 31: Latin America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 32: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 33: Europe Market Value Share, By Product Type, 2024 (E)
Figure 34: Europe Market Value Share, By End User, 2024 (E)
Figure 35: Europe Market Value Share, By Country, 2024 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2018 to 2023
Figure 37: Europe Market Value Forecast (US$ Mn), 2024 to 2034
Figure 38: Europe Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 39: Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 40: Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 41: South Asia Market Value Share, By Product Type, 2024 (E)
Figure 42: South Asia Market Value Share, By End User, 2024 (E)
Figure 43: South Asia Market Value Share, By Country, 2024 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2018 to 2023
Figure 45: South Asia Market Value Forecast (US$ Mn), 2024 to 2034
Figure 46: South Asia Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 47: South Asia Market Attractiveness Analysis by End User, 2024 to 2034
Figure 48: South Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 49: East Asia Market Value Share, By Product Type, 2024 (E)
Figure 50: East Asia Market Value Share, By End User, 2024 (E)
Figure 51: East Asia Market Value Share, By Country, 2024 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2018 to 2023
Figure 53: East Asia Market Value Forecast (US$ Mn), 2024 to 2034
Figure 54: East Asia Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 55: East Asia Market Attractiveness Analysis by End User, 2024 to 2034
Figure 56: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 57: Oceania Market Value Share, By Product Type, 2024 (E)
Figure 58: Oceania Market Value Share, By End User, 2024 (E)
Figure 59: Oceania Market Value Share, By Country, 2024 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2018 to 2023
Figure 61: Oceania Market Value Forecast (US$ Mn), 2024 to 2034
Figure 62: Oceania Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 63: Oceania Market Attractiveness Analysis by End User, 2024 to 2034
Figure 64: Oceania Market Attractiveness Analysis by Country, 2024 to 2034
Figure 65: Middle East and Africa Market Value Share, By Product Type, 2024 (E)
Figure 66: Middle East and Africa Market Value Share, By End User, 2024 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2024 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2018 to 2023
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2024 to 2034
Figure 70: Middle East and Africa Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 71: Middle East and Africa Market Attractiveness Analysis by End User, 2024 to 2034
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: UNITED STATES Market Value Analysis (US$ Mn), 2024 & 2034
Figure 74: UNITED STATES Market Value Share, By Product Type, 2024 (E)
Figure 75: UNITED STATES Market Value Share, By End User, 2024 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2024 & 2034
Figure 77: Canada Market Value Share, By Product Type, 2024 (E)
Figure 78: Canada Market Value Share, By End User, 2024 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2024 & 2034
Figure 80: Mexico Market Value Share, By Product Type, 2024 (E)
Figure 81: Mexico Market Value Share, By End User, 2024 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2024 & 2034
Figure 83: Brazil Market Value Share, By Product Type, 2024 (E)
Figure 84: Brazil Market Value Share, By End User, 2024 (E)
Figure 85: UNITED KINGDOM Market Value Analysis (US$ Mn), 2024 & 2034
Figure 86: UNITED KINGDOM Market Value Share, By Product Type, 2024 (E)
Figure 87: UNITED KINGDOM Market Value Share, By End User, 2024 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2024 & 2034
Figure 89: Germany Market Value Share, By Product Type, 2024 (E)
Figure 90: Germany Market Value Share, By End User, 2024 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2024 & 2034
Figure 92: France Market Value Share, By Product Type, 2024 (E)
Figure 93: France Market Value Share, By End User, 2024 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2024 & 2034
Figure 95: Italy Market Value Share, By Product Type, 2024 (E)
Figure 96: Italy Market Value Share, By End User, 2024 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2024 & 2034
Figure 98: Spain Market Value Share, By Product Type, 2024 (E)
Figure 99: Spain Market Value Share, By End User, 2024 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2024 & 2034
Figure 101: Russia Market Value Share, By Product Type, 2024 (E)
Figure 102: Russia Market Value Share, By End User, 2024 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2024 & 2034
Figure 104: China Market Value Share, By Product Type, 2024 (E)
Figure 105: China Market Value Share, By End User, 2024 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2024 & 2034
Figure 107: Japan Market Value Share, By Product Type, 2024 (E)
Figure 108: Japan Market Value Share, By End User, 2024 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2024 & 2034
Figure 110: South Korea Market Value Share, By Product Type, 2024 (E)
Figure 111: South Korea Market Value Share, By End User, 2024 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2024 & 2034
Figure 113: India Market Value Share, By Product Type, 2024 (E)
Figure 114: India Market Value Share, By End User, 2024 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2024 & 2034
Figure 116: ASEAN Market Value Share, By Product Type, 2024 (E)
Figure 117: ASEAN Market Value Share, By End User, 2024 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2024 & 2034
Figure 119: Australia Market Value Share, By Product Type, 2024 (E)
Figure 120: Australia Market Value Share, By End User, 2024 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2024 & 2034
Figure 122: New Zealand Market Value Share, By Product Type, 2024 (E)
Figure 123: New Zealand Market Value Share, By End User, 2024 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2024 & 2034
Figure 125: GCC Countries Market Value Share, By Product Type, 2024 (E)
Figure 126: GCC Countries Market Value Share, By End User, 2024 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2024 & 2034
Figure 128: Turkey Market Value Share, By Product Type, 2024 (E)
Figure 129: Turkey Market Value Share, By End User, 2024 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2024 & 2034
Figure 131: South Africa Market Value Share, By Product Type, 2024 (E)
Figure 132: South Africa Market Value Share, By End User, 2024 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the rheumatoid arthritis market size in 2024?
The global market for rheumatoid arthritis drugs stands at US$ 857.5 million in 2024.
What is the projected revenue from rheumatoid drug sales for 2034?
By 2034, worldwide revenue from rheumatoid arthritis drug sales is projected to reach US$ 1.56 billion.
How fast are RA drug sales projected to increase?
RA drug sales are forecasted to increase at 6.2% CAGR through 2034.
What is the forecast for the market in North America?
The market in North America has been forecasted to increase at 5.6% CAGR from 2024 to 2034.
At what rate is the market projected to expand in East Asia?
The market in East Asia is projected to expand at a CAGR of 6.4% from 2024 to 2034.
What are the projections for the market in Japan?
The market in Japan is forecasted to rise at a CAGR of 6.9% from 2024 to 2034.
Rheumatoid Arthritis Market